This article covers a hopeful new development in ALS research: a late-stage trial of the drug pridopidine, why researchers are focused on early, rapidly progressing patients, key results from the earlier phase 2 trial, safety signals and common side effects, and comments from lead investigators and ALS advocates about what this trial could mean for patients.
Amyotrophic lateral sclerosis, or ALS, slowly erases the brain’s connection to muscles and strips away basic abilities like walking, talking and breathing. Early symptoms often include muscle weakness, stiffness and cramping, and progression varies widely between individuals. Diagnosis typically occurs between ages 40 and 70, and many patients remain mentally alert even as the disease advances.
The PREVAiLS phase 3 trial has just enrolled its first participant under the supervision of Sabrina Paganoni at Mass General Brigham, marking a visible step forward for the program. The global study plans to recruit about 500 people at up to 60 ALS centers across 13 countries, focusing on those with early, rapidly progressing disease. Trial designers hope this targeted approach will reveal drug effects more clearly than a broader enrollment strategy would allow.
ACTOR ERIC DANE’S DEATH FROM ALS SPARKS URGENT FOCUS ON RAPID DECLINE sits squarely in the background of renewed urgency, reminding the public that ALS can devastate fast. The PREVAiLS team points to prior phase 2 data showing no overall benefit across the entire study population, while also finding encouraging signals in a subgroup of early, fast-declining patients. Those subgroup signals are the reason the phase 3 study concentrates on an early rapid-progressor population rather than casting a wider net.
“Pridopidine is a sigma-1 receptor (S1R) agonist,” Paganoni said, describing the drug’s mechanism of action. The sigma-1 receptor is linked to several neuroprotective pathways, and researchers believe modulating it could help counteract processes that go wrong in neurodegenerative diseases. That biological rationale is what pushed pridopidine into larger testing despite mixed phase 2 results.
“Enrolling the first participant in this confirmatory study is a milestone in our search for potential new therapeutic options that may help to slow disease progression, preserve function, maintain speech and prolong survival – key aims of early ALS therapy,” she said. Paganoni also warned that definitive answers depend on the full phase 3 readout, which will take time and thorough analysis before any conclusions can be drawn.
The earlier HEALEY phase 2 platform trial did not meet its primary endpoint across all participants, but it did show that pridopidine was generally well tolerated and safe relative to placebo. Falls and muscle weakness were the most commonly reported adverse events, which overlap with ALS symptoms and complicate interpretation. Those safety data gave teams enough confidence to press into a confirmatory study with refined enrollment criteria.
Experts from patient advocacy groups emphasize the importance of earlier diagnosis and intervention. “The earlier we can diagnose and treat ALS, the greater the potential to preserve function and maintain quality of life for longer, which is key to making ALS livable until we can cure it,” said Kuldip Dave of The ALS Association. He called the search for new treatment options an urgent need and praised patients and families who participate in trials.
“It was discouraging to see a lack of overall effect in the phase 2 study population,” he added. “However, we were encouraged to see positive signals emerge from various subgroups, including potential impacts on speech and respiratory function.” Respiratory decline is a leading cause of ALS-related death, so even modest preservation of breathing capacity can change both quality of life and survival outcomes.
Prilenia, the company developing pridopidine, and its trial partners argue that neurodegenerative damage becomes increasingly irreversible as disease advances, which is why the trial targets early, fast-progressing cases. The goal is to evaluate drug effect within a time-limited clinical trial where change is measurable and meaningful. If the phase 3 results confirm the subgroup benefits seen earlier, it could open a path to a new therapy for a subset of ALS patients.
ALS remains a grim diagnosis for most: “always fatal,” as many experts note, and typical survival after diagnosis is three to five years for most patients. About 20% live five years or longer, and roughly 5% survive beyond 20 years. With no cure or proven treatment that stops disease progression, every carefully designed trial and every enrolled patient matters in the long fight to turn ALS from a terminal condition to a manageable disease.
